{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:38:22Z","timestamp":1792150702657,"version":"4.4.0"},"reference-count":10,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T00:00:00Z","timestamp":1453680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2016,3]]},"abstract":"Abstract<\/jats:title>\n \n \n \n Within PrefHer (\n NCT<\/jats:styled-content>\n 01401166), patients and healthcare professionals (\n HCP<\/jats:styled-content>\n s) preferred subcutaneous (\n SC<\/jats:styled-content>\n ) over intravenous (\n IV<\/jats:styled-content>\n ) trastuzumab. We undertook a prospective, observational time and motion study to quantify patients\u2019 time in infusion chairs and active\n HCP<\/jats:styled-content>\n time in PrefHer. Patients with\n HER<\/jats:styled-content>\n 2\u2010positive early breast cancer received four adjuvant cycles of\n SC<\/jats:styled-content>\n trastuzumab (600\u00a0mg fixed dose via\n SC<\/jats:styled-content>\n single\u2010use injection device [\n SID<\/jats:styled-content>\n , Cohort 1] or\n SC<\/jats:styled-content>\n handheld syringe [\n HHS<\/jats:styled-content>\n , Cohort 2]) then four cycles of standard\n IV<\/jats:styled-content>\n trastuzumab or the reverse sequence. Generic case report forms for\n IV<\/jats:styled-content>\n and\n SC<\/jats:styled-content>\n management, both in the treatment room and the drug preparation area, were tailored to reflect center practices. Patient chair time and active\n HCP<\/jats:styled-content>\n time were recorded. We compared pooled Cohort 1\u00a0+\u00a02\n IV<\/jats:styled-content>\n with Cohort 1\n SC SID<\/jats:styled-content>\n and Cohort 2\n SC HHS<\/jats:styled-content>\n mean times across eight countries and individually within them utilizing a random intercept generalized linear mixed\u2010effects model. Per session, the\n SC SID<\/jats:styled-content>\n saved a mean of 57\u00a0min of patient chair time versus\n IV<\/jats:styled-content>\n (range across countries: 47\u201386;\n P\u00a0<\/jats:italic>\n <\n \u00a0<\/jats:italic>\n 0.0001); the\n SC HHS<\/jats:styled-content>\n saved 55\u00a0min (40\u201381;\n P\u00a0<\/jats:italic>\n <\n \u00a0<\/jats:italic>\n 0.0001). Active\n HCP<\/jats:styled-content>\n time was reduced by a mean of 13\u00a0min per session with the\n SC SID<\/jats:styled-content>\n (range across countries: 4\u201316;\n P\u00a0<\/jats:italic>\n <\n \u00a0<\/jats:italic>\n 0.0001) and 17\u00a0min with the\n SC HHS<\/jats:styled-content>\n (5\u201328;\n P\u00a0<\/jats:italic>\n <\n \u00a0<\/jats:italic>\n 0.0001) versus\n IV<\/jats:styled-content>\n .\n SC<\/jats:styled-content>\n trastuzumab, delivered via\n SID<\/jats:styled-content>\n or\n HHS<\/jats:styled-content>\n , saved patient chair and active\n HCP<\/jats:styled-content>\n times versus\n IV<\/jats:styled-content>\n infusion, supporting a transition to either\n SC<\/jats:styled-content>\n method.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/cam4.573","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T02:16:40Z","timestamp":1453688200000},"page":"389-397","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["A time and motion study of subcutaneous versus intravenous trastuzumab in patients with\n HER<\/scp>\n 2\u2010positive early breast cancer"],"prefix":"10.1002","volume":"5","author":[{"given":"Erwin","family":"De Cock","sequence":"first","affiliation":[{"name":"United BioSource Corporation Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pivot","sequence":"additional","affiliation":[{"name":"CHU Jean Minjoz Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik","family":"Hauser","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics Kantonsspital Baden AG Baden Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Verma","sequence":"additional","affiliation":[{"name":"Sunnybrook Odette Cancer Centre Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Persefoni","family":"Kritikou","sequence":"additional","affiliation":[{"name":"United BioSource Corporation Hammersmith United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Millar","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Knoop","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,1,25]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Ferlay J. I.Soerjomataram M.Ervik et\u00a0al.GLOBOCAN 2012 v1.0 Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Available athttp:\/\/globocan.iarc.fr(accessed 18 January 2016)."},{"key":"e_1_2_7_3_1","unstructured":"National Comprehensive Cancer Network.2016.NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V1.2016. Available athttp:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf(accessed 12 January 2016)."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv298"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv221"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70329-7"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2273-z"},{"key":"e_1_2_7_8_1","unstructured":"European Medicines Agency.Herceptin. Summary of product characteristics. Available athttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPARProduct_Information\/human\/000278\/WC500074922.pdf(18 January 2016)."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70383-8"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu364"},{"key":"e_1_2_7_11_1","first-page":"S385","article-title":"Reasons for patients\u2019 preferences for subcutaneous or intravenous trastuzumab in the PrefHer study","volume":"49","author":"Fallowfield L.","year":"2013","journal-title":"Eur. J. Cancer"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.573","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T19:52:49Z","timestamp":1696621969000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,25]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1002\/cam4.573"],"URL":"https:\/\/doi.org\/10.1002\/cam4.573","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,25]]},"assertion":[{"value":"2015-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}